The potential role of daptomycin and quinupristindalfopristin as a bactericidal agent in the treatment of methicillin-resistant <i>Staphylococcus aureus</i> bacteremia

Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia presents considerable clinical problems owing to elevated morbidity, mortality, and antibiotic resistance. This study evaluates the bactericidal efficacy of daptomycin and quinupristin-dalfopristin as potential treatments for MRSA bacteremia. Materials and Methods: This observational study, conducted from September 2017 to March 2018 at a tertiary care referral center in Northern India, analyzed 75 blood isolates of S. aureus . The Kirby–Bauer disc diffusion method and minimum inhibitory concentration testing were used to evaluate antimicrobial susceptibility by the Clinical and Laboratory Standards Institute 2017 standards. A statistical analysis compared the resistance patterns of MRSA and MRSA. Statistical analysis: The results showed that MRSA was much more resistant to aminoglycosides, fluoroquinolones, macrolides, and lincosamides than methicillin-susceptible S. aureus (MSSA), accounting for 70.66% of isolates ( P &lt; 0.05). Results: All isolates were completely susceptible to daptomycin; however, MRSA was more resistant to quinupristin-dalfopristin (69.81%) than MSSA (18.18%) ( P = 0.00004). Conclusions: The results show that daptomycin is a safer and more effective treatment for MRSA bacteremia, but quinupristin-dalfopristin is still a good option in some situations, even though its resistance rates are higher. The research emphasizes the necessity for customized antimicrobial approaches, continuous monitoring, and combination therapy to address multidrug-resistant MRSA. Quinupristin-dalfopristin may be considered in refractory infections; however, daptomycin is the recommended treatment due to its persistent effectiveness against MRSA. Strategic antibiotic stewardship and novel therapy strategies are essential for enhancing outcomes.